Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Rickli

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Clinical Chemistry|March 4, 2016
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HFSandra Sanders-van Wijk, Serge Masson, Valentina Milani, et al.
Circulation. Heart Failure|December 20, 2013
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHFSandra Sanders-van Wijk, Micha T Maeder, Fabian Nietlispach, et al.
Frontiers in Cardiovascular Medicine|August 1, 2022
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)Isabella Sudano, Francois Mach, Tiziano Moccetti, et al.
American Heart Journal|February 28, 2016
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trialGiuseppe Vassalli, Catherine Klersy, Stefano De Servi, et al.
American Heart Journal|December 3, 2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durationsRaban V Jeger, Matthias E Pfisterer, Rikke Sørensen, et al.
American Heart Journal|March 20, 2012
Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapyMicha T Maeder, Hans Rickli, Matthias E Pfisterer, et al.
JACC. Heart Failure|March 14, 2014
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Sandra Sanders-van Wijk, Antoinette D I van Asselt, Hans Rickli, et al.
Journal of the American College of Cardiology|November 10, 2012
Prognostic value of self-reported versus objectively measured functional capacity in patients with heart failure: results from the TIME-CHF (Trial of Intensified Versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Martijn A Spruit, Micha T Maeder, Christian Knackstedt, et al.
JACC. Basic to Translational Science|January 13, 2026
Cardiopathogenic T Cells Govern Progression and Functional Remodeling in Inflammatory Cardiomyopathy and Chronic MyocarditisAnna Joachimbauer, Nadine Cadosch, Cristina Gil-Cruz, et al.
European Heart Journal|November 10, 2011
End-of-life preferences of elderly patients with chronic heart failureHans-Peter Brunner-La Rocca, Peter Rickenbacher, Stefano Muzzarelli, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Clinical Chemistry|March 4, 2016
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HFSandra Sanders-van Wijk, Serge Masson, Valentina Milani, et al.
Circulation. Heart Failure|December 20, 2013
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHFSandra Sanders-van Wijk, Micha T Maeder, Fabian Nietlispach, et al.
Frontiers in Cardiovascular Medicine|August 1, 2022
Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)Isabella Sudano, Francois Mach, Tiziano Moccetti, et al.
American Heart Journal|February 28, 2016
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trialGiuseppe Vassalli, Catherine Klersy, Stefano De Servi, et al.
American Heart Journal|December 3, 2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durationsRaban V Jeger, Matthias E Pfisterer, Rikke Sørensen, et al.
American Heart Journal|March 20, 2012
Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapyMicha T Maeder, Hans Rickli, Matthias E Pfisterer, et al.
JACC. Heart Failure|March 14, 2014
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Sandra Sanders-van Wijk, Antoinette D I van Asselt, Hans Rickli, et al.
Journal of the American College of Cardiology|November 10, 2012
Prognostic value of self-reported versus objectively measured functional capacity in patients with heart failure: results from the TIME-CHF (Trial of Intensified Versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Martijn A Spruit, Micha T Maeder, Christian Knackstedt, et al.
JACC. Basic to Translational Science|January 13, 2026
Cardiopathogenic T Cells Govern Progression and Functional Remodeling in Inflammatory Cardiomyopathy and Chronic MyocarditisAnna Joachimbauer, Nadine Cadosch, Cristina Gil-Cruz, et al.
European Heart Journal|November 10, 2011
End-of-life preferences of elderly patients with chronic heart failureHans-Peter Brunner-La Rocca, Peter Rickenbacher, Stefano Muzzarelli, et al.
Pageof 20